Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 2/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 9/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11916051 | 0.76 | HRH4 (0.37) | HRH4PLATSLC18A3SIGMAR1HTR2C | |
| SCHEMBL11916023 | 0.75 | HTR2C (0.45) | PLATSLC18A3SIGMAR1HTR2C | |
| SCHEMBL23858239 | 0.75 | HTR2C (0.40) | HRH4SLC18A3SIGMAR1HTR2CMEN1 | |
| SCHEMBL30011048 | 0.75 | HTR2C (0.40) | HRH4SLC18A3SIGMAR1HTR2CMEN1 | |
| SCHEMBL15787084 | 0.74 | HTR2C (0.45) | HRH4PLATSLC18A3SIGMAR1HTR2C | |
| SCHEMBL20037971 | 0.73 | HRH4 (0.40) | HRH4SLC18A3SIGMAR1HTR2CHRH3 | |
| SCHEMBL21045972 | 0.73 | HRH4 (0.47) | HRH4SLC18A3SIGMAR1HTR2CHRH3 | |
| SCHEMBL31639401 | 0.73 | USP7 (0.43) | HRH4SLC18A3SIGMAR1HTR2CHRH3 | |
| SCHEMBL13934264 | 0.73 | BPTF (0.44) | HRH4SLC18A3SIGMAR1HTR2CHRH3 | |
| SCHEMBL21288252 | 0.72 | GLS (0.41) | HRH4SLC18A3SIGMAR1HTR2CHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | HRH4 1763/4885PLAT 2189/4885SLC18A3 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.